ArticleCureus2026
Sustained Complete Remission After a Single Cycle of R-CHOP in Extranodal Diffuse Large B-Cell Lymphoma of the Mandible: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive yet potentially curable malignancy when treated with standard multi-cycle R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin hydrochloride (Hydroxydaunorubicin), Vincristine sulfate (Oncovin), and Prednisolone/Prednisone) chemo-immunotherapy. Durable remission after incomplete or abbreviated therapy is exceptionally uncommon. We report the case of a 38-year-old man diagnosed with extranodal DLBCL of the mandible who received one cycle of R-CHOP before discontinuing therapy due to loss of insurance coverage. He was lost to follow-up and later re-presented with mild local symptoms. Restaging with contrast-enhanced computed tomography of the neck, chest, abdomen, and pelvis, along with magnetic resonance imaging of the brain and face, demonstrated no evidence of residual, recurrent, or disseminated disease. Laboratory studies, including complete blood count, comprehensive metabolic panel, and lactate dehydrogenase, were within normal limits. The patient has been in sustained complete clinical and radiologic remission for 24 months after a single cycle of R-CHOP. This case highlights the rarity of durable remission after minimal therapy in DLBCL and supports further investigation into biologic mechanisms associated with exceptional responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.